628326-05-6 Usage
Uses
Used in Pharmaceutical Development:
4-(4-Bromo-2-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester is used as a potential drug candidate for the treatment of central nervous system disorders due to its unique structural features that may offer therapeutic benefits.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-(4-Bromo-2-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester is utilized as a building block in organic synthesis for drug discovery and development, given its bromo and formyl functional groups that can be further modified to create new pharmaceutical agents.
Used in the Study of Antipsychotic Properties:
4-(4-Bromo-2-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester is studied for its potential antipsychotic properties, which could contribute to the development of new treatments for psychiatric conditions.
Used in the Study of Anticonvulsant Properties:
4-(4-Bromo-2-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester is also being investigated for its potential anticonvulsant properties, which may lead to advancements in the treatment of epilepsy and other seizure disorders.
Note: Since the exact biological and pharmacological properties of 4-(4-Bromo-2-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester are still under investigation, the applications listed are based on its potential uses in the field of medicinal chemistry and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 628326-05-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,8,3,2 and 6 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 628326-05:
(8*6)+(7*2)+(6*8)+(5*3)+(4*2)+(3*6)+(2*0)+(1*5)=156
156 % 10 = 6
So 628326-05-6 is a valid CAS Registry Number.
628326-05-6Relevant articles and documents
SOLUBLE GUANYLATE CYCLASE ACTIVATORS
-
Paragraph 0255; 0256, (2013/08/28)
This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
